Fortitude Family Office’s Recursion Pharmaceuticals RXRX Stock Holding History

Fortitude Family Office’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.81K	Buy	+1,038	New	+$3.46K	﹤0.01%	1208
2025 Q3	–	Sell	-87	Closed	-$440	–	2115
2025 Q2	$440	Buy	+87	New	+$427	﹤0.01%	1867
2024 Q3	–	Sell	-81	Closed	-$608	–	1263
2024 Q2	$608	Buy	+81	New	+$706	﹤0.01%	914

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IIA

Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return

Fortitude Family Office's RXRX Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 1,038 shares worth $3.81K. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in RXRX as recently as Q2 2025.

Fortitude Family Office first reported a position in RXRX in Q2 2024 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Fortitude Family Office held 1,038 shares of Recursion Pharmaceuticals worth $3.81K as of Q2 2026.
Recursion Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1208 holding.
Fortitude Family Office first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
26 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.